XPH(SZ:300147)2022-12-07 08:36Group 1: Company Development Strategy - The company focuses on the development of traditional Chinese medicine modernization as its strategic direction, emphasizing endogenous growth, external expansion, business model innovation, and leading-edge technology as four driving forces [3][4] - The company has competitive advantages in the development strategy, operational mechanism, management model, technology, and marketing aspects of the traditional Chinese medicine sector [3] Group 2: Clinical Research and Collaborations - The first phase of the clinical research project on specific T cell adoptive immunotherapy for solid tumors in collaboration with 458 hospitals has been completed, with the initial clinical summary report drafted [4] - The company is cautiously pursuing mergers and acquisitions as a path for external development, focusing on companies that complement its products, technology, and channels [4] Group 3: Employee Stock Ownership and Banking Progress - The first phase of the employee stock ownership plan is being implemented according to the asset management contract [5] - The establishment of Huacheng Bank is currently in the application process [5]